[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487014":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":25,"armGroups":26,"interventions":35,"overallOfficials":22,"centralContacts":41,"locations":47,"responsibleParty":63,"collaborators":22,"id":66,"slug":22,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":22,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":22,"enrollmentInfo":74,"targetDuration":22,"studyType":77,"phases":22,"briefSummary":78,"conditions":79,"keywords":22,"overallStatus":50,"whyStopped":22,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"RenJi Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Pathologic Complete Response","ypT0 ypN0, ypT0\u002Fis ypN0","at surgery",[14,18],{"measure":15,"description":16,"timeFrame":17},"Objective response rate","the rate of complete response and partial response","from the start of pre-operative treatment until the completion of surgery up to 6 months",{"measure":19,"description":20,"timeFrame":21},"Disease-free Survival","Disease-free survival time is defined as the time from date of randomization until the first occurrence of disease recurrence, distant metastasis and death from any cause.","From surgery until time of event up to 8 years",null,{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":24,"timePerspective":6,"maskingInfo":22},"COHORT","The study population will be selected from the hospital where they are treated",[27,32],{"label":28,"type":22,"description":29,"interventionNames":30},"early breast cancer","no requirements for therapy",[31],"Drug: pre-operative therapy",{"label":33,"type":22,"description":29,"interventionNames":34},"advanced breast cancer",[31],[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":22},"DRUG","pre-operative therapy","pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy",[33,28],[42],{"name":43,"role":44,"phone":45,"phoneExt":22,"email":46},"Wenjin Yin","CONTACT","86(21)68385569","yinwenjin@renji.com",[48],{"facility":49,"status":50,"city":51,"state":22,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":56,"coordinates":57},"Point",[58,59],121.45806,31.22222,{"lat":59,"lon":58},[62],{"name":43,"role":44,"phone":45,"phoneExt":22,"email":46},{"type":64,"investigatorFullName":43,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100487014",false,"NCT05621564","Pre-operative Therapy in Breast Cancer","The Effect of Pre-operative Therapy on Response and Survival in Breast Cancer","Inclusion Criteria:\n\n* Female, Aged ≥18 years\n* Histologically confirmed primary breast cancer\n* Plan to receive pre-operative therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of neurological or psychological disease, including epilepsy or dementia\n* Not suitable to participate in this study judged by investigators","FEMALE","18 Years",{"count":75,"type":76},488,"ESTIMATED","OBSERVATIONAL","This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.",[80],"Breast Cancer","2026-02-01",{"date":83,"type":84},"2026-02-03","ACTUAL",{"date":86,"type":84},"2022-11-01",{"date":88,"type":76},"2030-11",{"name":5,"class":6},1]